Literature DB >> 18403759

Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function.

Carole Ober1, Zheng Tan, Ying Sun, Jennifer D Possick, Lin Pan, Raluca Nicolae, Sadie Radford, Rodney R Parry, Andrea Heinzmann, Klaus A Deichmann, Lucille A Lester, James E Gern, Robert F Lemanske, Dan L Nicolae, Jack A Elias, Geoffrey L Chupp.   

Abstract

BACKGROUND: The chitinase-like protein YKL-40 is involved in inflammation and tissue remodeling. We recently showed that serum YKL-40 levels were elevated in patients with asthma and were correlated with severity, thickening of the subepithelial basement membrane, and pulmonary function. We hypothesized that single-nucleotide polymorphisms (SNPs) that affect YKL-40 levels also influence asthma status and lung function.
METHODS: We carried out a genomewide association study of serum YKL-40 levels in a founder population of European descent, the Hutterites, and then tested for an association between an implicated SNP and asthma and lung function. One associated variant was genotyped in a birth cohort at high risk for asthma, in which YKL-40 levels were measured from birth through 5 years of age, and in two populations of unrelated case patients of European descent with asthma and controls.
RESULTS: A promoter SNP (-131C-->G) in CHI3L1, the chitinase 3-like 1 gene encoding YKL-40, was associated with elevated serum YKL-40 levels (P=1.1 x 10(-13)), asthma (P=0.047), bronchial hyperresponsiveness (P=0.002), and measures of pulmonary function (P=0.046 to 0.002) in the Hutterites. The same SNP could be used to predict the presence of asthma in the two case-control populations (combined P=1.2 x 10(-5)) and serum YKL-40 levels at birth (in cord-blood specimens) through 5 years of age in the birth cohort (P=8.9 x 10(-3) to 2.5 x 10(-4)).
CONCLUSIONS: CHI3L1 is a susceptibility gene for asthma, bronchial hyperresponsiveness, and reduced lung function, and elevated circulating YKL-40 levels are a biomarker for asthma and decline in lung function. Copyright 2008 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18403759      PMCID: PMC2629486          DOI: 10.1056/NEJMoa0708801

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  21 in total

1.  Broad and narrow heritabilities of quantitative traits in a founder population.

Authors:  M Abney; M S McPeek; C Ober
Journal:  Am J Hum Genet       Date:  2001-04-10       Impact factor: 11.025

2.  A second-generation genomewide screen for asthma-susceptibility alleles in a founder population.

Authors:  C Ober; A Tsalenko; R Parry; N J Cox
Journal:  Am J Hum Genet       Date:  2000-10-05       Impact factor: 11.025

3.  Quantitative-trait homozygosity and association mapping and empirical genomewide significance in large, complex pedigrees: fasting serum-insulin level in the Hutterites.

Authors:  Mark Abney; Carole Ober; Mary Sara McPeek
Journal:  Am J Hum Genet       Date:  2002-03-04       Impact factor: 11.025

4.  The genetic dissection of complex traits in a founder population.

Authors:  C Ober; M Abney; M S McPeek
Journal:  Am J Hum Genet       Date:  2001-10-03       Impact factor: 11.025

5.  Novel case-control test in a founder population identifies P-selectin as an atopy-susceptibility locus.

Authors:  Catherine Bourgain; Sabine Hoffjan; Raluca Nicolae; Dina Newman; Lori Steiner; Karen Walker; Rebecca Reynolds; Carole Ober; Mary Sara McPeek
Journal:  Am J Hum Genet       Date:  2003-08-15       Impact factor: 11.025

6.  Best linear unbiased allele-frequency estimation in complex pedigrees.

Authors:  Mary Sara McPeek; Xiaodong Wu; Carole Ober
Journal:  Biometrics       Date:  2004-06       Impact factor: 2.571

Review 7.  The childhood origins of asthma (COAST) study.

Authors:  Robert F Lemanske
Journal:  Pediatr Allergy Immunol       Date:  2002       Impact factor: 6.377

8.  Identification of proteins secreted by human osteoblastic cells in culture.

Authors:  J S Johansen; M K Williamson; J S Rice; P A Price
Journal:  J Bone Miner Res       Date:  1992-05       Impact factor: 6.741

9.  Ethnic differences in asthma and associated phenotypes: collaborative study on the genetics of asthma.

Authors:  L A Lester; S S Rich; M N Blumenthal; A Togias; S Murphy; F Malveaux; M E Miller; G M Dunston; J Solway; R L Wolf; J M Samet; D G Marsh; D A Meyers; C Ober; E R Bleecker
Journal:  J Allergy Clin Immunol       Date:  2001-09       Impact factor: 10.793

10.  Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation.

Authors:  Zhou Zhu; Tao Zheng; Robert J Homer; Yoon-Keun Kim; Ning Yuan Chen; Lauren Cohn; Qutayba Hamid; Jack A Elias
Journal:  Science       Date:  2004-06-11       Impact factor: 47.728

View more
  212 in total

1.  Proteomic analysis of bronchoalveolar lavage fluid proteins from mice infected with Francisella tularensis ssp. novicida.

Authors:  Susan M Varnum; Bobbie-Jo M Webb-Robertson; Joel G Pounds; Ronald J Moore; Richard D Smith; Charles W Frevert; Shawn J Skerrett; David Wunschel
Journal:  J Proteome Res       Date:  2012-06-22       Impact factor: 4.466

2.  PDE11A associations with asthma: results of a genome-wide association scan.

Authors:  Andrew T DeWan; Elizabeth W Triche; Xuming Xu; Ling-I Hsu; Connie Zhao; Kathleen Belanger; Karen Hellenbrand; Saffron A G Willis-Owen; Miriam Moffatt; William O C Cookson; Blanca E Himes; Scott T Weiss; W James Gauderman; James W Baurley; Frank Gilliland; Jemma B Wilk; George T O'Connor; David P Strachan; Josephine Hoh; Michael B Bracken
Journal:  J Allergy Clin Immunol       Date:  2010-10       Impact factor: 10.793

3.  Fungal exposure modulates the effect of polymorphisms of chitinases on emergency department visits and hospitalizations.

Authors:  Ann Chen Wu; Jessica Lasky-Su; Christine A Rogers; Barbara J Klanderman; Augusto A Litonjua
Journal:  Am J Respir Crit Care Med       Date:  2010-06-10       Impact factor: 21.405

4.  Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation.

Authors:  Dafna Bonneh-Barkay; Stephanie J Bissel; Julia Kofler; Adam Starkey; Guoji Wang; Clayton A Wiley
Journal:  Brain Pathol       Date:  2011-12-22       Impact factor: 6.508

5.  Alternaria induces STAT6-dependent acute airway eosinophilia and epithelial FIZZ1 expression that promotes airway fibrosis and epithelial thickness.

Authors:  Taylor A Doherty; Naseem Khorram; Kotaro Sugimoto; Dean Sheppard; Peter Rosenthal; Jae Youn Cho; Alexa Pham; Marina Miller; Michael Croft; David H Broide
Journal:  J Immunol       Date:  2012-02-10       Impact factor: 5.422

6.  Resequencing candidate genes implicates rare variants in asthma susceptibility.

Authors:  Dara G Torgerson; Daniel Capurso; Rasika A Mathias; Penelope E Graves; Ryan D Hernandez; Terri H Beaty; Eugene R Bleecker; Benjamin A Raby; Deborah A Meyers; Kathleen C Barnes; Scott T Weiss; Fernando D Martinez; Dan L Nicolae; Carole Ober
Journal:  Am J Hum Genet       Date:  2012-02-10       Impact factor: 11.025

Review 7.  Update in asthma 2009.

Authors:  Wendy C Moore; Rodolfo M Pascual
Journal:  Am J Respir Crit Care Med       Date:  2010-06-01       Impact factor: 21.405

8.  eQTL mapping identifies insertion- and deletion-specific eQTLs in multiple tissues.

Authors:  Jinyan Huang; Jun Chen; Jorge Esparza; Jun Ding; James T Elder; Goncalo R Abecasis; Young-Ae Lee; G Mark Lathrop; Miriam F Moffatt; William O C Cookson; Liming Liang
Journal:  Nat Commun       Date:  2015-05-08       Impact factor: 14.919

Review 9.  New Insights Into the Relationship Between Chitinase-3-Like-1 and Asthma.

Authors:  Daniel Elieh Ali Komi; Tohid Kazemi; Anton Pieter Bussink
Journal:  Curr Allergy Asthma Rep       Date:  2016-08       Impact factor: 4.806

10.  Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation.

Authors:  Kristoffer Mads Henningsen; Brian Nilsson; Julia S Johansen; Xu Chen; Steen Pehrson; Jesper Hastrup Svendsen
Journal:  Inflamm Res       Date:  2009-12-10       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.